#BEGIN_DRUGCARD DB00697

# AHFS_Codes:
12:20.00

# ATC_Codes:
M03BX02

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Sirdalud
Ternelin
Zanaflex

# CAS_Registry_Number:
51322-75-9

# ChEBI_ID:
Not Available

# Chemical_Formula:
C9H8ClN5S

# Chemical_IUPAC_Name:
5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2259893

# Description:
Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Adrenergic alpha-Agonists
Analgesics
Anticonvulsants
Muscle Relaxants
Muscle Relaxants, Central
Parasympatholytics
Skeletal Muscle Relaxants

# Drug_Interactions:
Amiodarone	Amiodarone may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Amlodipine	Amlopidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Benazepril	Tizanidine increases the risk of hypotension with the ACE inhibitor
Captopril	Tizanidine increases the risk of hypotension with the ACE inhibitor
Cilazapril	Tizanidine increases the risk of hypotension with the ACE inhibitor
Cimetidine	Cimetidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Ciprofloxacin	Ciprofloxacin inhibits the metabolism and clearance of Tizanidine. Concomitant therapy is contraindicated.
Diclofenac	Diclofenac may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Donepezil	Possible antagonism of action
Enalapril	Tizanidine increases the risk of hypotension with the ACE inhibitor
Ethanol	Ethanol increases the adverse effects of Tizanidine. The CNS depressant effects of these agents are additive.
Ethinyl Estradiol	Ethinyl estradiol may increase the serum concentration of tizanidine. Monitor for changes in the therapeutic and adverse effects of tizanidine if ethinyl estradiol is initiated, discontinued or dose changed.
Fluoxetine	Fluoxetine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Fluvoxamine	Fluvoxamine inhibits the metabolism and clearance of tizanidine. Concomitant therapy is contraindicated.
Fosinopril	Tizanidine increases the risk of hypotension with the ACE inhibitor
Galantamine	Possible antagonism of action
Gemfibrozil	Gemfibrozil may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Ketoconazole	Ketoconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Lidocaine	Lidocaine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Lisinopril	Tizanidine increases the risk of hypotension with the ACE inhibitor
Mestranol	Oral contraceptives decrease the clearance of Tizanidine.
Methoxsalen	Methoxsalen may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Mexiletine	Mexilitene may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Miconazole	Miconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Moexipril	Tizanidine increases the risk of hypotension with the ACE inhibitor
Moxifloxacin	Moxifloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Nifedipine	Nifedipine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Norethindrone	The contraceptive increases the effect of tizanidine
Norfloxacin	Norfloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Ofloxacin	Ofloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Perindopril	Tizanidine increases the risk of hypotension with the ACE inhibitor
Primaquine	Primaquine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Propafenone	Propafenone may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Propofol	Propofol may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Quinapril	Tizanidine increases the risk of hypotension with the ACE inhibitor
Quinupristin	This combination presents an increased risk of toxicity
Ramipril	Tizanidine increases the risk of hypotension with the ACE inhibitor
Rivastigmine	Possible antagonism of action
Spirapril	Tizanidine increases the risk of hypotension with the ACE inhibitor
Thiabendazole	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Tizanidine by decreasing Tizanidine metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Tizanidine if Thiabendazole is initiated, discontinued or dose changed.
Ticlopidine	Ticlopidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Trandolapril	Tizanidine increases the risk of hypotension with the ACE inhibitor
Tranylcypromine	Tranylcypromine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
Treprostinil	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Trimipramine	Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Tizandine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Tizandine should be withdrawn very gradually to reduce the risk of hypertensive crisis.
Triprolidine	The CNS depressants, Triprolidine and Tizanidine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.4

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Tizanidine

# HET_ID:
Not Available

# Half_Life:
2.5 hours

# InChI_Identifier:
InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)

# InChI_Key:
InChIKey=XFYDIVBRZNQMJC-UHFFFAOYSA-N

# Indication:
For the management of increased muscle tone associated with spasticity

# KEGG_Compound_ID:
C07452

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
697

# Mechanism_Of_Action:
Tizanidine reduces spasticity by increasing presynaptic inhibition of motor neurons through agonist action at a2-adrenergic receptor sites.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
253.711

# Molecular_Weight_Mono:
253.018893678

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451701

# Pharmacology:
Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.

# Predicted_LogP_Hydrophobicity:
1.6

# Predicted_LogS:
-3.3

# Predicted_Water_Solubility:
1.33e-01 g/l

# Primary_Accession_No:
DB00697

# Protein_Binding:
30%

# PubChem_Compound_ID:
5487

# PubChem_Substance_ID:
46505373

# RxList_Link:
http://www.rxlist.com/cgi/generic/tizanidine.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00128

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Tizanidina [INN-Spanish]
Tizanidine Hcl
Tizanidinum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:33 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Tizanidine

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP1A2

# Phase_1_Metabolizing_Enzyme_1_ID:
4200

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 1A2

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P05177

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
8930173	Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
ADRA2A

# Drug_Target_1_GenBank_ID_Gene:
M23533

# Drug_Target_1_GenBank_ID_Protein:
178196

# Drug_Target_1_GeneCard_ID:
ADRA2A

# Drug_Target_1_Gene_Name:
ADRA2A

# Drug_Target_1_Gene_Sequence:
>1353 bp
ATGGGCTCCCTGCAGCCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGG
GGCGGCGCCCGGGCCACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCC
GGCCTGCTCATGCTGCTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACG
AGCCGCGCGCTCAAGGCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATC
CTGGTGGCCACGCTCGTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTAC
TTCGGCAAGGCTTGGTGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCC
ATCGTGCACCTGTGCGCCATCAGCCTGGACCGCTACTGGTCCATCACACAGGCCATCGAG
TACAACCTGAAGCGCACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATC
TCGGCCGTCATCTCCTTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGC
CCGCAGCCGGCCGAGCCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCG
TGCATCGGCTCCTTCTTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTAC
CAGATCGCCAAGCGTCGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCC
GCGCCGCCGGGGGGCACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGC
CCGGGGGGCGCAGAGGCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCC
GCGCCGGCCGGGCCGCGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGAC
CACGCCGAGCGGCCTCCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAAG
GCCCGAGCGAGCCAGGTGAAGCCGGGCGACAGCCTGCGCGGCGCGGGCCGGGGGCGACGG
GGATCGGGACGCCGGCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGGCGTCGC
GCTGGCGCGGGCGGGCAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTGGTCATC
GGAGTGTTCGTGGTGTGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCGTCGGG
TGCTCCGTGCCACGCACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAGCTCG
TTGAACCCGGTCATCTACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAAGATC
CTCTGTCGGGGGGACAGGAAGCGGATCGTGTGA

# Drug_Target_1_General_Function:
Involved in alpha2-adrenergic receptor activity

# Drug_Target_1_General_References:
11888275	Chung DA, Zuiderweg ER, Fowler CB, Soyer OS, Mosberg HI, Neubig RR: NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: evidence for a novel cytoplasmic helix. Biochemistry. 2002 Mar 19;41(11):3596-604.
1678390	Suryanarayana S, Daunt DA, Von Zastrow M, Kobilka BK: A point mutation in the seventh hydrophobic domain of the alpha 2 adrenergic receptor increases its affinity for a family of beta receptor antagonists. J Biol Chem. 1991 Aug 15;266(23):15488-92.
1678850	Wang CD, Buck MA, Fraser CM: Site-directed mutagenesis of alpha 2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol Pharmacol. 1991 Aug;40(2):168-79.
1849485	Chhajlani V, Rangel N, Uhlen S, Wikberg JE: Identification of an additional gene belonging to the alpha 2 adrenergic receptor family in the human genome by PCR. FEBS Lett. 1991 Mar 25;280(2):241-4.
2170371	Guyer CA, Horstman DA, Wilson AL, Clark JD, Cragoe EJ Jr, Limbird LE: Cloning, sequencing, and expression of the gene encoding the porcine alpha 2-adrenergic receptor. Allosteric modulation by Na+, H+, and amiloride analogs. J Biol Chem. 1990 Oct 5;265(28):17307-17.
2568356	Fraser CM, Arakawa S, McCombie WR, Venter JC: Cloning, sequence analysis, and permanent expression of a human alpha 2-adrenergic receptor in Chinese hamster ovary cells. Evidence for independent pathways of receptor coupling to adenylate cyclase attenuation and activation. J Biol Chem. 1989 Jul 15;264(20):11754-61.
2823383	Kobilka BK, Matsui H, Kobilka TS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ, Regan JW: Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor. Science. 1987 Oct 30;238(4827):650-6.

# Drug_Target_1_HGNC_ID:
HGNC:281

# Drug_Target_1_HPRD_ID:
00078

# Drug_Target_1_ID:
318

# Drug_Target_1_Locus:
10q24-q26

# Drug_Target_1_Molecular_Weight:
48957

# Drug_Target_1_Name:
Alpha-2A adrenergic receptor

# Drug_Target_1_Number_of_Residues:
450

# Drug_Target_1_PDB_ID:
1HOF

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Alpha-2A adrenergic receptor
MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFT
SRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSS
IVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGG
PQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVA
APPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSD
HAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKAS
RWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSS
LNPVIYTIFNHDFRRAFKKILCRGDRKRIV

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol

# Drug_Target_1_SwissProt_ID:
P08913

# Drug_Target_1_SwissProt_Name:
ADA2A_HUMAN

# Drug_Target_1_Synonyms:
Alpha-2 adrenergic receptor subtype C10
Alpha-2A adrenoceptor
Alpha-2A adrenoreceptor
Alpha-2AAR

# Drug_Target_1_Theoretical_pI:
10.20

# Drug_Target_1_Transmembrane_Regions:
34-59
71-96
107-129
150-173
193-217
375-399
407-430

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
8930173	Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
ADRA2B

# Drug_Target_2_GenBank_ID_Gene:
M34041

# Drug_Target_2_GenBank_ID_Protein:
178198

# Drug_Target_2_GeneCard_ID:
ADRA2B

# Drug_Target_2_Gene_Name:
ADRA2B

# Drug_Target_2_Gene_Sequence:
>1353 bp
ATGGACCACCAGGACCCCTACTCCGTGCAGGCCACAGCGGCCATAGCGGCGGCCATCACC
TTCCTCATTCTCTTTACCATCTTCGGCAACGCTCTGGTCATCCTGGCTGTGTTGACCAGC
CGCTCGCTGCGCGCCCCTCAGAACCTGTTCCTGGTGTCGCTGGCCGCCGCCGACATCCTG
GTGGCCACGCTCATCATCCCTTTCTCGCTGGCCAACGAGCTGCTGGGCTACTGGTACTTC
CGGCGCACGTGGTGCGAGGTGTACCTGGCGCTCGACGTGCTCTTCTGCACCTCGTCCATC
GTGCACCTGTGCGCCATCAGCCTGGACCGCTACTGGGCCGTGAGCCGCGCGCTGGAGTAC
AACTCCAAGCGCACCCCGCGCCGCATCAAGTGCATCATCCTCACTGTGTGGCTCATCGCC
GCCGTCATCTCGCTGCCGCCCCTCATCTACAAGGGCGACCAGGGCCCCCAGCCGCGCGGG
CGCCCCCAGTGCAAGCTCAACCAGGAGGCCTGGTACATCCTGGCCTCCAGCATCGGATCT
TTCTTTGCTCCTTGCCTCATCATGATCCTTGTCTACCTGCGCATCTACCTGATCGCCAAA
CGCAGCAACCGCAGAGGTCCCAGGGCCAAGGGGGGGCCTGGGCAGGGTGAGTCCAAGCAG
CCCCGACCCGACCATGGTGGGGCTTTGGCCTCAGCCAAACTGCCAGCCCTGGCCTCTGTG
GCTTCTGCCAGAGAGGTCAACGGACACTCGAAGTCCACTGGGGAGAAGGAGGAGGGGGAG
ACCCCTGAAGATACTGGGACCCGGGCCTTGCCACCCAGTTGGGCTGCCCTTCCCAACTCA
GGCCAGGGCCAGAAGGAGGGTGTTTGTGGGGCATCTCCAGAGGATGAAGCTGAAGAGGAG
GAAGAGGAGGAGGAGGAGGAGGAAGAGTGTGAACCCCAGGCAGTGCCAGTGTCTCCGGCC
TCAGCTTGCAGCCCCCCGCTGCAGCAGCCACAGGGCTCCCGGGTGCTGGCCACCCTACGT
GGCCAGGTGCTCCTGGGCAGGGGCGTGGGTGCTATAGGTGGGCAGTGGTGGCGTCGAAGG
GCGCACGTGACCCGGGAGAAGCGCTTCACCTTCGTGCTGGCTGTGGTCATTGGCGTTTTT
GTGCTCTGCTGGTTCCCCTTCTTCTTCAGCTACAGCCTGGGCGCCATCTGCCCGAAGCAC
TGCAAGGTGCCCCATGGCCTCTTCCAGTTCTTCTTCTGGATCGGCTACTGCAACAGCTCA
CTGAACCCTGTTATCTACACCATCTTCAACCAGGACTTCCGCCGTGCCTTCCGGAGGATC
CTGTGCCGCCCGTGGACCCAGACGGCCTGGTGA

# Drug_Target_2_General_Function:
Involved in alpha2-adrenergic receptor activity

# Drug_Target_2_General_References:
2164221	Lomasney JW, Lorenz W, Allen LF, King K, Regan JW, Yang-Feng TL, Caron MG, Lefkowitz RJ: Expansion of the alpha 2-adrenergic receptor family: cloning and characterization of a human alpha 2-adrenergic receptor subtype, the gene for which is located on chromosome 2. Proc Natl Acad Sci U S A. 1990 Jul;87(13):5094-8.
2172775	Weinshank RL, Zgombick JM, Macchi M, Adham N, Lichtblau H, Branchek TA, Hartig PR: Cloning, expression, and pharmacological characterization of a human alpha 2B-adrenergic receptor. Mol Pharmacol. 1990 Nov;38(5):681-8.
2173582	Chang AC, Ho TF, Chang NC: In vitro amplification by polymerase chain reaction of a partial gene encoding the third subtype of alpha-2 adrenergic receptor in humans. Biochem Biophys Res Commun. 1990 Oct 30;172(2):817-23.

# Drug_Target_2_HGNC_ID:
HGNC:282

# Drug_Target_2_HPRD_ID:
00086

# Drug_Target_2_ID:
629

# Drug_Target_2_Locus:
2p13-q13

# Drug_Target_2_Molecular_Weight:
49954

# Drug_Target_2_Name:
Alpha-2B adrenergic receptor

# Drug_Target_2_Number_of_Residues:
450

# Drug_Target_2_PDB_ID:
1HOF

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_2_Protein_Sequence:
>Alpha-2B adrenergic receptor
MDHQDPYSVQATAAIAAAITFLILFTIFGNALVILAVLTSRSLRAPQNLFLVSLAAADIL
VATLIIPFSLANELLGYWYFRRTWCEVYLALDVLFCTSSIVHLCAISLDRYWAVSRALEY
NSKRTPRRIKCIILTVWLIAAVISLPPLIYKGDQGPQPRGRPQCKLNQEAWYILASSIGS
FFAPCLIMILVYLRIYLIAKRSNRRGPRAKGGPGQGESKQPRPDHGGALASAKLPALASV
ASAREVNGHSKSTGEKEEGETPEDTGTRALPPSWAALPNSGQGQKEGVCGASPEDEAEEE
EEEEEEEEECEPQAVPVSPASACSPPLQQPQGSRVLATLRGQVLLGRGVGAIGGQWWRRR
AQLTREKRFTFVLAVVIGVFVLCWFPFFFSYSLGAICPKHCKVPHGLFQFFFWIGYCNSS
LNPVIYTIFNQDFRRAFRRILCRPWTQTAW

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phentolamine > mianserine > spiperone > prazosin > alprenolol > propanolol > pindolol

# Drug_Target_2_SwissProt_ID:
P18089

# Drug_Target_2_SwissProt_Name:
ADA2B_HUMAN

# Drug_Target_2_Synonyms:
Alpha-2 adrenergic receptor subtype C2
Alpha-2B adrenoceptor
Alpha-2B adrenoreceptor

# Drug_Target_2_Theoretical_pI:
8.52

# Drug_Target_2_Transmembrane_Regions:
13-38
50-75
86-108
131-153
170-193
373-396
406-429

# Drug_Target_3_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
8930173	Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
ADRA2C

# Drug_Target_3_GenBank_ID_Gene:
J03853

# Drug_Target_3_GenBank_ID_Protein:
178194

# Drug_Target_3_GeneCard_ID:
ADRA2C

# Drug_Target_3_Gene_Name:
ADRA2C

# Drug_Target_3_Gene_Sequence:
>1386 bp
ATGGCGTCCCCGGCGCTGGCGGCGGCGCTGGCGGTGGCGGCAGCGGCGGGCCCCAATGCG
AGCGGCGCGGGCGAGAGGGGCAGCGGCGGGGTTGCCAATGCCTCGGGGGCTTCCTGGGGG
CCGCCGCGCGGCCAGTACTCGGCGGGCGCGGTGGCAGGGCTGGCTGCCGTGGTGGGCTTC
CTCATCGTCTTCACCGTGGTGGGCAACGTGCTGGTGGTGATCGCCGTGCTGACCAGCCGG
GCGCTGCGCGCGCCACAGAACCTCTTCCTGGTGTCGCTGGCCTCGGCCGACATCCTGGTG
GCCACGCTGGTCATGCCCTTCTCGTTGGCCAACGAGCTCATGGCCTACTGGTACTTCGGG
CAGGTGTGGTGCGGCGTGTACCTGGCGCTCGATGTGCTGTTTTGCACCTCGTCGATCGTG
CATCTGTGTGCCATCAGCCTGGACCGCTACTGGTCGGTGACGCAGGCCGTCGAGTACAAC
CTGAAGCGCACACCACGCCGCGTCAAGGCCACCATCGTCGCCGTGTGGCTCATCTCGGCC
GTCATCTCCTTCCCGCCGCTGGTCTCGCTCTACCGCCAGCCCGACGGCGCCGCCTACCCG
CAGTGCGGCCTCAACGACGAGACCTGGTACATCCTGTCCTCCTGCATCGGCTCCTTCTTC
GCGCCCTGCCTCATCATGGGCCTGGTCTACGCGCGCATCTACCGAGTGGCCAAGCGTCGC
ACGCGCACGCTCAGCGAGAAGCGCGCCCCCGTGGGCCCCGACGGTGCGTCCCCGACTACC
GAAAACGGGCTGGGCGCGGCGGCAGGCGAGGCGAGAACGGGCACTGCGCGCCCCCGCCCG
CCGACGTGGAGCCGGACGAGAGCAGCGCAGCGGCCGAGAGGCGGCGCGCCGGGGCCGTTG
CGGCGGGGCGGGCGGCGGCGAGCGGGCGCGGAGGGGGGCGCGGGCGGTGCGGACGGGCAG
GGGGCGGGGCCGGGGGCGGCTCAGTCGGGGGCGCTGACCGCCTCCAGGTCCCCGGGGCCC
GGTGGCCGCCTCTCGCGCGCCAGCTCGCGCTCCGTCGAGTTCTTCCTGTCGCGCCGGCGC
CGGGCGCGCAGCAGCGTGTGCCGCCGCAAGGTGGCCCAGGCGCGCGAGAAGCGCTTCACC
TTTGTGCTGGCTGTGGTCATGGGCGTGTTCGTGCTCTGCTGGTTCCCCTTCTTCTTCATC
TACAGCCTGTACGGCATCTGCCGCGAGGCCTGCCAGGTGCCCGGCCCGCTCTTCAAGTTC
TTCTTCTGGATCGGCTACTGCAACAGCTCGCTCAACCCGGTCATCTACACGGTCTTCAAC
CAGGATTTCCGGCCATCCTTCAAGCACATCCTCTTCCGACGGAGGAGAAGGGGCTTCAGG
CAGTGA

# Drug_Target_3_General_Function:
Involved in alpha2-adrenergic receptor activity

# Drug_Target_3_General_References:
10801795	Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB: A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem. 2000 Jul 28;275(30):23059-64.
1849485	Chhajlani V, Rangel N, Uhlen S, Wikberg JE: Identification of an additional gene belonging to the alpha 2 adrenergic receptor family in the human genome by PCR. FEBS Lett. 1991 Mar 25;280(2):241-4.
2842764	Regan JW, Kobilka TS, Yang-Feng TL, Caron MG, Lefkowitz RJ, Kobilka BK: Cloning and expression of a human kidney cDNA for an alpha 2-adrenergic receptor subtype. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6301-5.
9371698	Schaak S, Devedjian JC, Cayla C, Sender Y, Paris H: Molecular cloning, sequencing and functional study of the promoter region of the human alpha2C4-adrenergic receptor gene. Biochem J. 1997 Dec 1;328 ( Pt 2):431-8.

# Drug_Target_3_HGNC_ID:
HGNC:283

# Drug_Target_3_HPRD_ID:
00085

# Drug_Target_3_ID:
378

# Drug_Target_3_Locus:
4p16

# Drug_Target_3_Molecular_Weight:
49523

# Drug_Target_3_Name:
Alpha-2C adrenergic receptor

# Drug_Target_3_Number_of_Residues:
462

# Drug_Target_3_PDB_ID:
1HOF

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_3_Protein_Sequence:
>Alpha-2C adrenergic receptor
MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGAVAGLAAVVGF
LIVFTVVGNVLVVIAVLTSRALRAPQNLFLVSLASADILVATLVMPFSLANELMAYWYFG
QVWCGVYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKATIVAVWLISA
VISFPPLVSLYRQPDGAAYPQCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAKLR
TRTLSEKRAPVGPDGASPTTENGLGAAAGAGENGHCAPPPADVEPDESSAAAERRRRRGA
LRRGGRRRAGAEGGAGGADGQGAGPGAAESGALTASRSPGPGGRLSRASSRSVEFFLSRR
RRARSSVCRRKVAQAREKRFTFVLAVVMGVFVLCWFPFFFSYSLYGICREACQVPGPLFK
FFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILFRRRRRGFRQ

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins

# Drug_Target_3_SwissProt_ID:
P18825

# Drug_Target_3_SwissProt_Name:
ADA2C_HUMAN

# Drug_Target_3_Synonyms:
Alpha-2 adrenergic receptor subtype C4
Alpha-2C adrenoceptor
Alpha-2C adrenoreceptor

# Drug_Target_3_Theoretical_pI:
10.69

# Drug_Target_3_Transmembrane_Regions:
52-76
89-114
125-147
169-191
208-231
380-407
421-441

# Drug_Target_4_Cellular_Location:
Cell membrane. Cytoplasm. Early endosome. Recycling endosome

# Drug_Target_4_Chromosome_Location:
3

# Drug_Target_4_Drug_References:
893017	Rolon PA: Myxoglobulosis of the appendix. Int Surg. 1977 Jun-Jul;62(6-7):355-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
AF082516

# Drug_Target_4_GenBank_ID_Protein:
3462807

# Drug_Target_4_GeneCard_ID:
NISCH

# Drug_Target_4_Gene_Name:
NISCH

# Drug_Target_4_Gene_Sequence:
>4515 bp
ATGGCGACCGCGCGCACCTTCGGGCCCGAGCGGGAAGCCGAGCCGGCCAAGGAAGCGCGC
GTCGTGGGCTCGGAGCTTGTGGACACTTATACGGTTTACATCATCCAGGTCACTGATGGC
AGCCATGAGTGGACAGTAAAGCACCGCTACAGCGACTTCCATGACCTGCATGAAAAGCTC
GTTGCAGAGAGAAAGATTGATAAAAACCTGCTTCCGCCCAAAAAGATAATTGGGAAAAAC
TCAAGAAGCTTGGTGGAGAAGAGGGAGAAGGATCTGGAGGTCTACCTCCAGAAGCTCCTG
GCTGCCTTCCCTGGCGTGACCCCCAGAGTACTGGCCCACTTCTTGCATTTTCACTTCTAT
GAGATAAATGGCATCACCGCGGCACTGGCTGAAGAGCTCTTTGAGAAAGGAGAACAGCTC
CTGGGGGCCGGCGAGGTCTTTGCCATTGGACCCCTGCAGCTGTATGCCGTCACGGAGCAG
CTGCAGCAGGGAAAGCCCACGTGCGCCAGTGGGGATGCCAAGACCGACCTCGGGCACATC
CTGGACTTCACCTGTCGCCTTAAGTACCTTAAGGTTTCTGGCACAGAAGGACCTTTTGGG
ACCAGCAACATTCAGGAGCAGCTCCTGCCGTTCGACCTATCAATATTCAAGTCCCTGCAT
CAGGTGGAGATAAGTCACTGTGATGCTAAGCACATCAGAGGGCTGGTCGCATCGAAGCCC
ACCTTAGCCACGCTGAGTGTCCGCTTCTCAGCAACCTCGATGAAGGAAGTCCTTGTTCCT
GAAGCCTCAGAATTTGATGAGTGGGAGCCTGAAGGCACAACCCTAGAAGGCCCTGTGACT
GCCGTCATCCCCACTTGGCAGGCATTGACCACGCTTGACCTGAGCCACAACAGCATCTCC
GAGATCGACGAGTCTGTGAAACTGATCCCAAAGATTGAGTTCCTGGACCTGAGTCACAAT
GGATTGCTGGTTGTGGACAATCTGCAGCACCTGTATAACCTTGTGCATCTGGACCTGTCC
TACAACAAGCTCTCCTCCTTGGAAGGGCTTCACACCAAGCTGGGGAACATCAAGACCTTA
AACCTGGCAGGCAACCTCCTAGAGAGTCTGAGTGGCCTGCACAAGCTCTACTCACTGGTC
AACCTGGATCTCCGGGACAACAGGATCGAACAGATGGAGGAGGTCCGGAGCATAGGCAGC
CTCCCGTGTCTGGAGCACGTGTCTCTGCTGAACAACCCTCTGAGCATCATCCCCGACTAC
CGGACCAAGGTGCTGGCTCAGTTCGGAGAGAGGGCCTCAGAGGTCTGTCTGGATGACACA
GTGACCACAGAGAAGGAGCTGGACACTGTGGAAGTGCTGAAAGCAATTCAGAAAGCCAAG
GAGGTCAAGTCCAAACTGAGCAACCCAGAGAAGAAGGGTGGTGAAGACTCCCGGCTCTCA
GCTGCCCCCTGCATCAGACCCAGCAGCTCCCCTCCCACTGTGGCTCCCGCATCTGCCTCC
CTGCCCCAGCCCATCCTCTCTAACCAAGGAATCATGTTCGTTCAGGAGGAGGCCCTGGCC
AGCAGCCTCTCGTCCACTGACAGTCTGACTCCCGAGCACCAGCCCATTGCCCAGGGATGT
TCTGATTCCTTGGAGTCCATCCCTGCGGGACAGGCAGCTTCCGATGATTTAAGGGACGTG
CCAGGAGCTGTTGGTGGTGCAAGCCCAGAACATGCCGAGCCGGAGGTCCAGGTGGTGCCG
GGGTCTGGCCAGATCATCTTCCTGCCCTTCACCTGCATTGGCTACACGGCCACCAATCAG
GACTTCATCCAGCGCCTGAGCACACTGATCCGGCAGGCCATCGAGCGGCAGCTGCCTGCC
TGGATCGAGGCTGCCAACCAGCGGGAGGAGGGCCAGGGTGAACAGGGCGAGGAGGAGGAT
GAGGAGGAGGAAGAAGAGGAGGACGTGGCTGAGAACCGCTACTTTGAAATGGGGCCCCCA
GACGTGGAGGAGGAGGAGGGAGGAGGCCAGGGGGAGGAAGAGGAGGAGGAAGAGGAGGAT
GAAGAGGCCGAGGAGGAGCGCCTGGCTCTGGAATGGGCCCTGGGCGCGGACGAGGACTTC
CTGCTGGAGCACATCCGCATCCTCAAGGTGCTGTGGTGCTTCCTGATCCATGTGCAGGGC
AGTATCCGCCAGTTCGCCGCCTGCCTTGTGCTCACCGACTTCGGCATCGCAGTCTTCGAG
ATCCCGCACCAGGAGTCTCGGGGCAGCAGCCAGCACATCCTCTCCTCCCTGCGCTTTGTC
TTTTGCTTCCCGCATGGCGACCTCACCGAGTTTGGCTTCCTCATGCCGGAGCTGTGTCTG
GTGCTCAAGGTACGGCACAGTGAGAACACGCTCTTCATTATCTCGGACGCCGCCAACCTG
CACGAGTTCCACGCGGACCTGCGCTCATGCTTTGCACCCCAGCACATGGCCATGCTGTGT
AGCCCCATCCTCTACGGCAGCCACACCAGCCTGCAGGAGTTCCTGCGCCAGCTGCTCACC
TTCTACAAGGTGGCTGGCGGCTGCCAGGAGCGCAGCCAGGGCTGCTTCCCCGTCTACCTG
GTCTACAGTGACAAGCGCATGGTGCAGACGGCCGCCGGGGACTACTCAGGCAACATCGAG
TGGGCCAGCTGCACACTCTGTTCAGCCGTGCGGCGCTCCTGCTGCGCGCCCTCTGAGGCC
GTCAAGTCCGCCGCCATCCCCTACTGGCTGTTGCTCACGCCCCAGCACCTCAACGTCATC
AAGGCCGACTTCAACCCCATGCCCAACCGTGGCACCCACAACTGTCGCAACCGCAACAGC
TTCAAGCTCAGCCGTGTGCCGCTCTCCACCGTGCTGCTGGACCCCACACGCAGCTGTACC
CAGCCTCGGGGCGCCTTTGCTGATGGCCACGTGCTAGAGCTGCTCGTGGGGTACCGCTTT
GTCACTGCCATCTTCGTGCTGCCCCACGAGAAGTTCCACTTCCTGCGCGTCTACAACCAG
CTGCGGGCCTCGCTGCAGGACCTGAAGACTGTGGTCATCGCCAAGACCCCCGGGACGGGA
GGCAGCCCCCAGGGCTCCTTTGCGGATGGCCAGCCTGCCGAGCGCAGGGCCAGCAATGAC
CAGCGTCCCCAGGAGGTCCCAGCAGAGGCTCTGGCCCCGGCCCCAGTGGAAGTCCCAGCT
CCAGCCCCTGCAGCAGCCTCAGCCTCAGGCCCAGCGAAGACTCCGGCCCCAGCAGAGGCC
TCAACTTCAGCTTTGGTCCCAGAGGAGACGCCAGTGGAAGCTCCAGCCCCACCCCCAGCC
GAGGCCCCTGCCCAGTACCCGAGTGAGCACCTCATCCAGGCCACCTCGGAGGAGAATCAG
ATCCCCTCGCACTTGCCTGCCTGCCCGTCGCTCCGGCACGTCGCCAGCCTGCGGGGCAGC
GCCATCATCGAGCTCTTCCACAGCAGCATTGCTGAGGTTGAAAACGAGGAGCTGAGGCAC
CTCATGTGGTCCTCGGTGGTGTTCTACCAGACCCCAGGGCTGGAGGTGACTGCCTGCGTG
CTGCTCTCCACCAAGGCTGTGTACTTTGTGCTCCACGACGGCCTCCGCCGCTACTTCTCA
GAGCCACTGCAGGATTTCTGGCATCAGAAAAACACCGACTACAACAACAGCCCTTTCCAC
ATCTCCCAGTGCTTCGTGCTAAAGCTTAGTGACCTGCAGTCAGTCAATGTGGGGCTTTTC
GACCAGCATTTCCGGCTGACGGGTTCCACCCCGATGCAGGTGGTCACGTGCTTGACGCGG
GACAGCTACCTGACGCACTGCTTCCTCCAGCACCTCATGGTCGTGCTGTCCTCTCTGGAA
CGCACGCCCTCGCCGGAGCCTGTTGACAAGGACTTCTACTCCGAGTTTGGGAACAAGACC
ACAGGGAAGATGGAGAACTACGAGCTGATCCACTCTAGTCGCGTCAAGTTTACCTACCCC
AGTGAGGAGGAGATTGGGGACCTGACGTTCACTGTGGCCCAAAAGATGGCTGAGCCAGAG
AAGGCCCCAGCCCTCAGCATCCTGCTGTACGTGCAGGCCTTCCAGGTGGGCATGCCACCC
CCTGGGTGCTGCAGGGGCCCCCTGCGCCCCAAGACACTCCTGCTCACCAGCTCCGAGATC
TTCCTCCTGGATGAGGACTGTGTCCACTACCCACTGCCCGAGTTTGCCAAAGAGCCGCCG
CAGAGAGACAGGTACCGGCTGGACGATGGCCGCCGCGTCCGGGACCTGGACCGAGTGCTC
ATGGGCTACCAGACCTACCCGCAGGCCCTCACCCTCGTCTTCGATGACGTGCAAGGTCAT
GACCTCATGGGCAGTGTCACCCTGGACCACTTTGGGGAGGTGCCAGGTGGCCCGGCTAGA
GCCAGCCAGGGCCGTGAAGTCCAGTGGCAGGTGTTTGTCCCCAGTGCTGAGAGCAGAGAG
AAGCTCATCTCGCTGTTGGCTCGCCAGTGGGAGGCCCTGTGTGGCCGTGAGCTGCCTGTC
GAGCTCACCGGCTAG

# Drug_Target_4_General_Function:
Involved in phosphoinositide binding

# Drug_Target_4_General_References:
10231032	Nagase T, Ishikawa K, Suyama M, Kikuno R, Hirosawa M, Miyajima N, Tanaka A, Kotani H, Nomura N, Ohara O: Prediction of the coding sequences of unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 1999 Feb 26;6(1):63-70.
10882231	Piletz JE, Ivanov TR, Sharp JD, Ernsberger P, Chang CH, Pickard RT, Gold G, Roth B, Zhu H, Jones JC, Baldwin J, Reis DJ: Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterization. DNA Cell Biol. 2000 Jun;19(6):319-29.
11912194	Sano H, Liu SC, Lane WS, Piletz JE, Lienhard GE: Insulin receptor substrate 4 associates with the protein IRAS. J Biol Chem. 2002 May 31;277(22):19439-47. Epub 2002 Mar 23.
14702039	Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.
15028621	Piletz JE, Deleersnijder W, Roth BL, Ernsberger P, Zhu H, Ziegler D: IRAS splice variants. Ann N Y Acad Sci. 2003 Dec;1009:419-26.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
16641997	Muzny DM, Scherer SE, Kaul R, Wang J, Yu J, Sudbrak R, Buhay CJ, Chen R, Cree A, Ding Y, Dugan-Rocha S, Gill R, Gunaratne P, Harris RA, Hawes AC, Hernandez J, Hodgson AV, Hume J, Jackson A, Khan ZM, Kovar-Smith C, Lewis LR, Lozado RJ, Metzker ML, Milosavljevic A, Miner GR, Morgan MB, Nazareth LV, Scott G, Sodergren E, Song XZ, Steffen D, Wei S, Wheeler DA, Wright MW, Worley KC, Yuan Y, Zhang Z, Adams CQ, Ansari-Lari MA, Ayele M, Brown MJ, Chen G, Chen Z, Clendenning J, Clerc-Blankenburg KP, Chen R, Chen Z, Davis C, Delgado O, Dinh HH, Dong W, Draper H, Ernst S, Fu G, Gonzalez-Garay ML, Garcia DK, Gillett W, Gu J, Hao B, Haugen E, Havlak P, He X, Hennig S, Hu S, Huang W, Jackson LR, Jacob LS, Kelly SH, Kube M, Levy R, Li Z, Liu B, Liu J, Liu W, Lu J, Maheshwari M, Nguyen BV, Okwuonu GO, Palmeiri A, Pasternak S, Perez LM, Phelps KA, Plopper FJ, Qiang B, Raymond C, Rodriguez R, Saenphimmachak C, Santibanez J, Shen H, Shen Y, Subramanian S, Tabor PE, Verduzco D, Waldron L, Wang J, Wang J, Wang Q, Williams GA, Wong GK, Yao Z, Zhang J, Zhang X, Zhao G, Zhou J, Zhou Y, Nelson D, Lehrach H, Reinhardt R, Naylor SL, Yang H, Olson M, Weinstock G, Gibbs RA: The DNA sequence, annotation and analysis of human chromosome 3. Nature. 2006 Apr 27;440(7088):1194-8.
17974005	Bechtel S, Rosenfelder H, Duda A, Schmidt CP, Ernst U, Wellenreuther R, Mehrle A, Schuster C, Bahr A, Blocker H, Heubner D, Hoerlein A, Michel G, Wedler H, Kohrer K, Ottenwalder B, Poustka A, Wiemann S, Schupp I: The full-ORF clone resource of the German cDNA Consortium. BMC Genomics. 2007 Oct 31;8:399.
9851558	Ivanov TR, Jones JC, Dontenwill M, Bousquet P, Piletz JE: Characterization of a partial cDNA clone detected by imidazoline receptor-selective antisera. J Auton Nerv Syst. 1998 Oct 15;72(2-3):98-110.

# Drug_Target_4_HGNC_ID:
GNC:18006

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
6070

# Drug_Target_4_Locus:
3p21.1

# Drug_Target_4_Molecular_Weight:
166641.1

# Drug_Target_4_Name:
Nischarin

# Drug_Target_4_Number_of_Residues:
1504

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00560	LRR_1
PF00787	PX

# Drug_Target_4_Protein_Sequence:
>Nischarin
MATARTFGPEREAEPAKEARVVGSELVDTYTVYIIQVTDGSHEWTVKHRYSDFHDLHEKL
VAERKIDKNLLPPKKIIGKNSRSLVEKREKDLEVYLQKLLAAFPGVTPRVLAHFLHFHFY
EINGITAALAEELFEKGEQLLGAGEVFAIGPLQLYAVTEQLQQGKPTCASGDAKTDLGHI
LDFTCRLKYLKVSGTEGPFGTSNIQEQLLPFDLSIFKSLHQVEISHCDAKHIRGLVASKP
TLATLSVRFSATSMKEVLVPEASEFDEWEPEGTTLEGPVTAVIPTWQALTTLDLSHNSIS
EIDESVKLIPKIEFLDLSHNGLLVVDNLQHLYNLVHLDLSYNKLSSLEGLHTKLGNIKTL
NLAGNLLESLSGLHKLYSLVNLDLRDNRIEQMEEVRSIGSLPCLEHVSLLNNPLSIIPDY
RTKVLAQFGERASEVCLDDTVTTEKELDTVEVLKAIQKAKEVKSKLSNPEKKGGEDSRLS
AAPCIRPSSSPPTVAPASASLPQPILSNQGIMFVQEEALASSLSSTDSLTPEHQPIAQGC
SDSLESIPAGQAASDDLRDVPGAVGGASPEHAEPEVQVVPGSGQIIFLPFTCIGYTATNQ
DFIQRLSTLIRQAIERQLPAWIEAANQREEGQGEQGEEEDEEEEEEEDVAENRYFEMGPP
DVEEEEGGGQGEEEEEEEEDEEAEEERLALEWALGADEDFLLEHIRILKVLWCFLIHVQG
SIRQFAACLVLTDFGIAVFEIPHQESRGSSQHILSSLRFVFCFPHGDLTEFGFLMPELCL
VLKVRHSENTLFIISDAANLHEFHADLRSCFAPQHMAMLCSPILYGSHTSLQEFLRQLLT
FYKVAGGCQERSQGCFPVYLVYSDKRMVQTAAGDYSGNIEWASCTLCSAVRRSCCAPSEA
VKSAAIPYWLLLTPQHLNVIKADFNPMPNRGTHNCRNRNSFKLSRVPLSTVLLDPTRSCT
QPRGAFADGHVLELLVGYRFVTAIFVLPHEKFHFLRVYNQLRASLQDLKTVVIAKTPGTG
GSPQGSFADGQPAERRASNDQRPQEVPAEALAPAPAEVPAPAPAAASASGPAKTPAPAEA
STSALVPEETPVEAPAPPPAEAPAQYPSEHLIQATSEENQIPSHLPACPSLRHVASLRGS
AIIELFHSSIAEVENEELRHLMWSSVVFYQTPGLEVTACVLLSTKAVYFVLHDGLRRYFS
EPLQDFWHQKNTDYNNSPFHISQCFVLKLSDLQSVNVGLFDQHFRLTGSTPMQVVTCLTR
DSYLTHCFLQHLMVVLSSLERTPSPEPVDKDFYSEFGNKTTGKMENYELIHSSRVKFTYP
SEEEIGDLTFTVAQKMAEPEKAPALSILLYVQAFQVGMPPPGCCRGPLRPKTLLLTSSEI
FLLDEDCVHYPLPEFAKEPPQRDRYRLDDGRRVRDLDRVLMGYQTYPQALTLVFDDVQGH
DLMGSVTLDHFGEVPGGPARASQGREVQWQVFVPSAESREKLISLLARQWEALCGRELPV
ELTG

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. Its activation by the agonist rilmenidine induces an increase in phosphorylation of mitogen-activated protein kinases MAPK1 and MAPK3 in rostral ventrolateral medulla (RVLM) neurons that exhibited rilmenidine-evoked hypotension (By similarity). Blocking its activation with efaroxan abolished rilmenidine-induced mitogen-activated protein kinase phosphorylation in RVLM neurons (By similarity). Acts as a modulator of Rac-regulated signal transduction pathways (By similarity). Suppresses Rac1-stimulated cell migration by interacting with PAK1 and inhibiting its kinase activity (By similarity). Also blocks Pak-independent Rac signaling by interacting with RAC1 and inhibiting Rac1-stimulated NF-kB response element and cyclin D1 promoter activation (By similarity). Inhibits also LIMK1 kinase activity by reducing LIMK1 'Tyr-508' phosphorylation (By similarity). Inhibits Rac-induced cell migration and invasion in breast and colon epithelial cells (By similarity). Inhibits lamellipodia formation, when overexpressed (By similarity). Plays a role in protection against apoptosis. Involved in association with IRS4 in the enhancement of insulin activation of MAPK1 and MAPK3. When overexpressed, induces a redistribution of cell surface ITGA5 integrin to intracellular endosomal structures

# Drug_Target_4_SwissProt_ID:
Q9Y2I1

# Drug_Target_4_SwissProt_Name:
NISCH_HUMAN

# Drug_Target_4_Synonyms:
I-1
I-1 receptor candidate protein
I1R
I1R candidate protein
IR1
Imidazoline receptor 1
Imidazoline receptor antisera-selected protein
Imidazoline-1 receptor
Imidazoline-1 receptor candidate protein
hIRAS

# Drug_Target_4_Theoretical_pI:
4.80

# Drug_Target_4_Transmembrane_Regions:
None

#END_DRUGCARD DB00697
